| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open … HS Rugo, F Lerebours, E Ciruelos, P Drullinsky, M Ruiz-Borrego, ... The Lancet Oncology 22 (4), 489-498, 2021 | 316 | 2021 |
| Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer JA Halpern, A Sedrakyan, WC Hsu, J Mao, TJ Daskivich, PL Nguyen, ... Cancer 122 (16), 2496-2504, 2016 | 83 | 2016 |
| Indications, utilization and complications following prostate biopsy: New York State analysis JA Halpern, A Sedrakyan, B Dinerman, WC Hsu, J Mao, JC Hu The Journal of urology 197 (4), 1020-1025, 2017 | 68 | 2017 |
| Contemporary incidence and outcomes of prostate cancer lymph node metastases AN Bernstein, JE Shoag, R Golan, JA Halpern, EM Schaeffer, WC Hsu, ... The Journal of urology 199 (6), 1510-1517, 2018 | 53 | 2018 |
| Predictors of acupuncture use among children and adolescents with cancer SK Chokshi, EJ Ladas, K Taromina, D McDaniel, D Rooney, Z Jin, ... Pediatric blood & cancer 64 (7), e26424, 2017 | 42 | 2017 |
| Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast Cancer S Turner, S Chia, H Kanakamedala, WC Hsu, J Park, D Chandiwana, ... The oncologist 26 (7), e1133-e1142, 2021 | 39 | 2021 |
| 90-day readmission after lumbar spinal fusion surgery in New York State between 2005 and 2014: a 10-year analysis of a statewide cohort AA Baaj, G Lang, WC Hsu, MJ Avila, J Mao, A Sedrakyan Spine 42 (22), 1706-1716, 2017 | 38 | 2017 |
| Surgeon annual and cumulative volumes predict early postoperative outcomes after brain tumor resection R Ramakrishna, WC Hsu, J Mao, A Sedrakyan World Neurosurgery 114, e254-e266, 2018 | 21 | 2018 |
| Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram‐negative Bloodstream Infections:“Every day matters” TP Lodise, H Kanakamedala, WC Hsu, B Cai Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (9 …, 2020 | 14 | 2020 |
| Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial LV Hampson, J Chu, A Zia, J Zhang, WC Hsu, CS Parzynski, Y Hao, ... Statistics in Biopharmaceutical Research 16 (1), 1-10, 2024 | 10 | 2024 |
| Definitive and sustained increase in prostate cancer metastases in the United States NA Patel, A Sedrakyan, F Bianco, R Etzioni, MA Gorin, WC Hsu, J Mao, ... Urologic Oncology: Seminars and Original Investigations 37 (12), 988-990, 2019 | 8 | 2019 |
| Comparison of clinical outcomes among patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel in the ELARA trial versus a real-world external … Y Hao, WC Hsu, CS Parzynski, C Lobetti Bodoni, E Degtyarev, ... Blood 138 (Supplement 1), 2419-2419, 2021 | 4 | 2021 |
| Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma Y Hao, WC Hsu, CS Parzynski, E Degtyarev, LV Hampson, A Masood, ... Journal of Comparative Effectiveness Research 12 (7), e220173, 2023 | 3 | 2023 |
| 309P Real-world effectiveness of alpelisib (ALP)+ fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal … S Turner, SKL Chia, H Kanakamedala, WC Hsu, J Park, D Chandiwana, ... Annals of Oncology 31, S366, 2020 | 3 | 2020 |
| INCREASE IN THE INCIDENCE OF ADVANCED PROSTATE CANCER IN THE UNITED STATES: MP14-15 J Shoag, A Sedrakyan, J Halpern, WC Hsu, J Hu Journal of Urology 197 (4), e167, 2017 | 2 | 2017 |
| ROLE OF UTERINE PRESERVING SURGERY IN MESH BASED PELVIC ORGAN PROLAPSE REPAIR.: MP10-08 J Forde, B Chughtai, B Stone, WC Hsu, J Mao, A Te, A Sedrakyan Journal of Urology 195 (4), e105, 2016 | 2 | 2016 |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open … HS Rugo, F Lerebours, E Ciruelos, P Drullinsky, M Ruiz-Borrego, ... The Lancet Oncology 25 (12), e629-e638, 2024 | 1 | 2024 |
| The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study WC Hsu, A Crowley, CS Parzynski BMC Medical Research Methodology 24 (1), 203, 2024 | 1 | 2024 |
| Selection of censoring schemes for analysing overall survival in real-world data with linked mortality information WC Hsu, A Crowley, S Oliveria, C Parzynski PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 303-304, 2022 | | 2022 |
| Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States NA Patel, A Sedrakyan, F Bianco, R Etzioni, MA Gorin, WC Hsu, J Mao, ... Urologic oncology 40 (7), 354, 2022 | | 2022 |
